Literature DB >> 2476140

T-cell reactivity in myasthenia gravis.

J Newsom-Davis1, G Harcourt, N Sommer, D Beeson, N Willcox, J B Rothbard.   

Abstract

In a proliferation assay, peripheral blood lymphocytes (PBL) from a relatively small proportion of myasthenia gravis (MG) patients and from controls responded to Torpedo acetylcholine receptor (T-AChR), which shows approximately 75% homology with the human AChR. Over 50% of MG patients responded to recombinant human AChR alpha-subunit (r37-437) however, compared with 9% of controls. A proportion of MG PBL respond to synthetic peptides of the extracellular portion of the human alpha-subunit, but only MG patients (18%) responded to the juxta-membrane sequence p257-269. MG T-cell lines raised against native T-AChR failed to respond to the synthetic peptides. These results underline the need to use human AChR sequences to test relevant T-cell reactivity in MG. T-cell lines raised from three MG patients to human alpha-subunit r37-437 have shown Stimulation Index (SI) values of 3.5-22. Three clones derived from one of these had SI values of 100-500. Preliminary testing of responsiveness in one of these clones showed reactivity to several recombinant polypeptides including r37-437 and r37-181, as in the parent line. The epitope(s) within this latter sequence have not yet been identified, but the experimental approach used here should make it possible to define critical T-cell epitopes in MG, and to determine their functional relevance by investigating the ability of AChR-reactive T-cell clones to provide specific help in anti-AChR antibody production.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476140     DOI: 10.1016/0896-8411(89)90121-2

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  11 in total

Review 1.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 2.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 3.  Autoimmune hepatitis. Definition--classification--histopathology--immunopathogenesis.

Authors:  K H Meyer zum Büschenfelde; H P Dienes
Journal:  Virchows Arch       Date:  1996-09       Impact factor: 4.064

4.  Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.

Authors:  S H Im; D Barchan; S Fuchs; M C Souroujon
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 5.  Update on myasthenia gravis.

Authors:  B R Thanvi; T C N Lo
Journal:  Postgrad Med J       Date:  2004-12       Impact factor: 2.401

6.  Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis.

Authors:  Matthew N Meriggioli; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

Review 7.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

8.  Myelin antigen reactive T cells in cerebrovascular diseases.

Authors:  W Z Wang; T Olsson; V Kostulas; B Höjeberg; H P Ekre; H Link
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

Review 9.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

10.  Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls.

Authors:  H Link; O Olsson; J Sun; W Z Wang; G Andersson; H P Ekre; T Brenner; O Abramsky; T Olsson
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.